ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Lecapon-Mepha Lactab®:Mepha Pharma AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
N04BA03 - Levodopa, Decarboxylase Inhibitor and Comt InhibitorATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N04 - Anti-Parkinson Drugs

This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.

The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.
No separate DDDs are established for oral depot formulations.

N04B - Dopaminergic Agents
 
N04BA - Dopa and Dopa Derivatives

Combinations with decarboxylase inhibitors and other dopaminergic agents are classified here.

The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.

N04BA03 - Levodopa, Decarboxylase Inhibitor and Comt Inhibitor
Concentr.Adm.RouteNote
0.45 gORefers to levodopa
2020 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home